Clinical Trial Update: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes [Phase 2]

View source ↗

Summary

Phase II trial evaluating lymphodepletion followed by infusion of anti-MART-1 F5 TCR-engineered T cells in metastatic melanoma has completed enrollment, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• anti-MART-1 F5 TCR-gene-engineered lymphocytes (TCR-engineered T cells targeting MART-1 (F5 TCR))

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-12-18